U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C38H47N5O7S2
Molecular Weight 749.9427
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SIMEPREVIR

SMILES

CC(C)c1csc(-c2cc(c3ccc(c(C)c3n2)OC)O[C@]4([H])C[C@]5([H])[C@@]([H])(C4)C(=O)N(C)CCCC/C(/[H])=C(/[H])\[C@]6([H])C[C@@]6(C(=NS(=O)(=O)C7CC7)O)N=C5O)n1

InChI

InChIKey=JTZZSQYMACOLNN-VDWJNHBNSA-N
InChI=1S/C38H47N5O7S2/c1-21(2)30-20-51-35(40-30)29-18-32(26-13-14-31(49-5)22(3)33(26)39-29)50-24-16-27-28(17-24)36(45)43(4)15-9-7-6-8-10-23-19-38(23,41-34(27)44)37(46)42-52(47,48)25-11-12-25/h8,10,13-14,18,20-21,23-25,27-28H,6-7,9,11-12,15-17,19H2,1-5H3,(H,41,44)(H,42,46)/b10-8-/t23-,24-,27-,28-,38-/m1/s1

HIDE SMILES / InChI
Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor approved for the treatment of Chronic Hepatitis C (genotype 1 and 4). Inhibiting NS3/4A, simeprevir blocks viral replication. In in vitro assays simeprevir was potent against HCV genotype 1a and 1b. Simeprevir must not be administered as monotherapy and should only be prescribed with both peginterferon alfa and ribavirin.

CNS Activity

Curator's Comment:: There was minimal penetration of the blood-brain barrier.

Originator

Curator's Comment:: Patent application WO2008092954A2 is a formulation patent, originally filed by Tibotec Pharmaceuticals, now part of Janssen Pharmaceuticals. The application claims a crystalline form of a substituted macro cyclic compound, preferably a variant of simeprevir, useful for the treatment of HCV infections.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q91RS4_9HEPC
0.359999999999999987 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
OLYSIO

Approved Use

Indicated for the treatment of chronic hepatitis C (CHC) genotype 1 or 4 infection as a component of a combination antiviral treatment regimen. OLYSIO monotherapy is not recommended.

Launch Date

1385078400000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
11470 ng/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SIMEPREVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2304 ng/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SIMEPREVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4067 ng/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SIMEPREVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6172 ng/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SIMEPREVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
206000 ng × h/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SIMEPREVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
24630 ng × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SIMEPREVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
56430 ng × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SIMEPREVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
79710 ng × h/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SIMEPREVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
41.32 h
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SIMEPREVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
16.04 h
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
SIMEPREVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day multiple, oral
dose: 200 mg 1 times / day
route: oral
experiment_type: multiple
dose_type:
co-adm with
    data_source:
    https://pubmed.ncbi.nlm.nih.gov/22326470
    unhealthy, 18–70 years
    population: unhealthy
    age: 18–70 years
    sex: M+F
    food_status:
    n:
    data_source:
    https://pubmed.ncbi.nlm.nih.gov/22326470
    Other AEs: Headache, Diarrhoea...
    Other AEs:
    Headache (13.5%)
    Diarrhoea (10.8%)
    Fatigue (10.8%)
    Pruritus (10.8%)
    Anorexia (8.1%)
    Back pain (8.1%)
    Myalgia (8.1%)

    data_source:
    https://pubmed.ncbi.nlm.nih.gov/22326470
    400 mg 1 times / day multiple, oral
    Highest studied dose
    dose: 400 mg 1 times / day
    route: oral
    experiment_type: multiple
    dose_type: Highest studied dose
    co-adm with
      data_source:
      https://pubmed.ncbi.nlm.nih.gov/19852962
      healthy, 24.0 years(range: 20-44 years)
      population: healthy
      age: 24.0 years(range: 20-44 years)
      sex: M+F
      food_status:
      n:
      data_source:
      https://pubmed.ncbi.nlm.nih.gov/19852962
      600 mg single, oral
      Highest studied dose
      dose: 600 mg
      route: oral
      experiment_type: single
      dose_type: Highest studied dose
      co-adm with
        data_source:
        https://pubmed.ncbi.nlm.nih.gov/19852962
        healthy, 38.0 years (range: 23-55 years)
        population: healthy
        age: 38.0 years (range: 23-55 years)
        sex: M
        food_status:
        n:
        data_source:
        https://pubmed.ncbi.nlm.nih.gov/19852962
        200 mg 2 times / day multiple, oral
        Highest studied dose
        dose: 200 mg 2 times / day
        route: oral
        experiment_type: multiple
        dose_type: Highest studied dose
        co-adm with
          data_source:
          https://pubmed.ncbi.nlm.nih.gov/19852962
          healthy, 38.0 years (range: 25-54 years)
          population: healthy
          age: 38.0 years (range: 25-54 years)
          sex: M+F
          food_status:
          n:
          data_source:
          https://pubmed.ncbi.nlm.nih.gov/19852962
          Other AEs: Photosensitivity reaction, Diarrhea...
          Other AEs:
          Photosensitivity reaction (3 patients)
          Diarrhea (2 patients)
          Abdominal pain upper (2 patients)

          data_source:
          https://pubmed.ncbi.nlm.nih.gov/19852962
          150 mg 1 times / day steady, oral
          Recommended
          dose: 150 mg 1 times / day
          route: oral
          experiment_type: steady
          dose_type: Recommended
          co-adm with
            data_source:
            https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000MedR.pdf
            unhealthy, 49 years (range: 18-73 years)
            population: unhealthy
            age: 49 years (range: 18-73 years)
            sex: M+F
            food_status:
            n:
            data_source:
            https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000MedR.pdf
            Disc. AE: Pruritus, Psoriasis...
            AEs leading to
            discontinuation/dose reduction:​
            Pruritus (<1)
            Psoriasis (<1)
            Rash (1%)
            Rash erythematous (<1)
            Skin burning sensation (<1)
            Aggression (<1)
            Blood bilirubin increased (<1)
            Major depression (<1)
            Stomatitis (<1)
            Headache (<1)
            Pain (<1)

            data_source:
            https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000MedR.pdf
            AEs

            AEs

            AESignificanceDosePopulation
            Rash 1%
            Disc. AE
            150 mg 1 times / day steady, oral
            Recommended
            dose: 150 mg 1 times / day
            route: oral
            experiment_type: steady
            dose_type: Recommended
            co-adm with
              data_source:
              https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000MedR.pdf
              unhealthy, 49 years (range: 18-73 years)
              Aggression <1%
              Disc. AE
              150 mg 1 times / day steady, oral
              Recommended
              dose: 150 mg 1 times / day
              route: oral
              experiment_type: steady
              dose_type: Recommended
              co-adm with
                data_source:
                https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000MedR.pdf
                unhealthy, 49 years (range: 18-73 years)
                Blood bilirubin increased <1%
                Disc. AE
                150 mg 1 times / day steady, oral
                Recommended
                dose: 150 mg 1 times / day
                route: oral
                experiment_type: steady
                dose_type: Recommended
                co-adm with
                  data_source:
                  https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000MedR.pdf
                  unhealthy, 49 years (range: 18-73 years)
                  Headache <1%
                  Disc. AE
                  150 mg 1 times / day steady, oral
                  Recommended
                  dose: 150 mg 1 times / day
                  route: oral
                  experiment_type: steady
                  dose_type: Recommended
                  co-adm with
                    data_source:
                    https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000MedR.pdf
                    unhealthy, 49 years (range: 18-73 years)
                    Major depression <1%
                    Disc. AE
                    150 mg 1 times / day steady, oral
                    Recommended
                    dose: 150 mg 1 times / day
                    route: oral
                    experiment_type: steady
                    dose_type: Recommended
                    co-adm with
                      data_source:
                      https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000MedR.pdf
                      unhealthy, 49 years (range: 18-73 years)
                      Pain <1%
                      Disc. AE
                      150 mg 1 times / day steady, oral
                      Recommended
                      dose: 150 mg 1 times / day
                      route: oral
                      experiment_type: steady
                      dose_type: Recommended
                      co-adm with
                        data_source:
                        https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000MedR.pdf
                        unhealthy, 49 years (range: 18-73 years)
                        Pruritus <1%
                        Disc. AE
                        150 mg 1 times / day steady, oral
                        Recommended
                        dose: 150 mg 1 times / day
                        route: oral
                        experiment_type: steady
                        dose_type: Recommended
                        co-adm with
                          data_source:
                          https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000MedR.pdf
                          unhealthy, 49 years (range: 18-73 years)
                          Psoriasis <1%
                          Disc. AE
                          150 mg 1 times / day steady, oral
                          Recommended
                          dose: 150 mg 1 times / day
                          route: oral
                          experiment_type: steady
                          dose_type: Recommended
                          co-adm with
                            data_source:
                            https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000MedR.pdf
                            unhealthy, 49 years (range: 18-73 years)
                            Rash erythematous <1%
                            Disc. AE
                            150 mg 1 times / day steady, oral
                            Recommended
                            dose: 150 mg 1 times / day
                            route: oral
                            experiment_type: steady
                            dose_type: Recommended
                            co-adm with
                              data_source:
                              https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000MedR.pdf
                              unhealthy, 49 years (range: 18-73 years)
                              Skin burning sensation <1%
                              Disc. AE
                              150 mg 1 times / day steady, oral
                              Recommended
                              dose: 150 mg 1 times / day
                              route: oral
                              experiment_type: steady
                              dose_type: Recommended
                              co-adm with
                                data_source:
                                https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000MedR.pdf
                                unhealthy, 49 years (range: 18-73 years)
                                Stomatitis <1%
                                Disc. AE
                                150 mg 1 times / day steady, oral
                                Recommended
                                dose: 150 mg 1 times / day
                                route: oral
                                experiment_type: steady
                                dose_type: Recommended
                                co-adm with
                                  data_source:
                                  https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000MedR.pdf
                                  unhealthy, 49 years (range: 18-73 years)
                                  Diarrhoea 10.8%
                                  200 mg 1 times / day multiple, oral
                                  dose: 200 mg 1 times / day
                                  route: oral
                                  experiment_type: multiple
                                  dose_type:
                                  co-adm with
                                    data_source:
                                    https://pubmed.ncbi.nlm.nih.gov/22326470
                                    unhealthy, 18–70 years
                                    population:
                                    age:
                                    sex:
                                    food_status:
                                    n:
                                    data_source:
                                    https://pubmed.ncbi.nlm.nih.gov/22326470
                                    Fatigue 10.8%
                                    200 mg 1 times / day multiple, oral
                                    dose: 200 mg 1 times / day
                                    route: oral
                                    experiment_type: multiple
                                    dose_type:
                                    co-adm with
                                      data_source:
                                      https://pubmed.ncbi.nlm.nih.gov/22326470
                                      unhealthy, 18–70 years
                                      population:
                                      age:
                                      sex:
                                      food_status:
                                      n:
                                      data_source:
                                      https://pubmed.ncbi.nlm.nih.gov/22326470
                                      Pruritus 10.8%
                                      200 mg 1 times / day multiple, oral
                                      dose: 200 mg 1 times / day
                                      route: oral
                                      experiment_type: multiple
                                      dose_type:
                                      co-adm with
                                        data_source:
                                        https://pubmed.ncbi.nlm.nih.gov/22326470
                                        unhealthy, 18–70 years
                                        population:
                                        age:
                                        sex:
                                        food_status:
                                        n:
                                        data_source:
                                        https://pubmed.ncbi.nlm.nih.gov/22326470
                                        Headache 13.5%
                                        200 mg 1 times / day multiple, oral
                                        dose: 200 mg 1 times / day
                                        route: oral
                                        experiment_type: multiple
                                        dose_type:
                                        co-adm with
                                          data_source:
                                          https://pubmed.ncbi.nlm.nih.gov/22326470
                                          unhealthy, 18–70 years
                                          population:
                                          age:
                                          sex:
                                          food_status:
                                          n:
                                          data_source:
                                          https://pubmed.ncbi.nlm.nih.gov/22326470
                                          Anorexia 8.1%
                                          200 mg 1 times / day multiple, oral
                                          dose: 200 mg 1 times / day
                                          route: oral
                                          experiment_type: multiple
                                          dose_type:
                                          co-adm with
                                            data_source:
                                            https://pubmed.ncbi.nlm.nih.gov/22326470
                                            unhealthy, 18–70 years
                                            population:
                                            age:
                                            sex:
                                            food_status:
                                            n:
                                            data_source:
                                            https://pubmed.ncbi.nlm.nih.gov/22326470
                                            Back pain 8.1%
                                            200 mg 1 times / day multiple, oral
                                            dose: 200 mg 1 times / day
                                            route: oral
                                            experiment_type: multiple
                                            dose_type:
                                            co-adm with
                                              data_source:
                                              https://pubmed.ncbi.nlm.nih.gov/22326470
                                              unhealthy, 18–70 years
                                              population:
                                              age:
                                              sex:
                                              food_status:
                                              n:
                                              data_source:
                                              https://pubmed.ncbi.nlm.nih.gov/22326470
                                              Myalgia 8.1%
                                              200 mg 1 times / day multiple, oral
                                              dose: 200 mg 1 times / day
                                              route: oral
                                              experiment_type: multiple
                                              dose_type:
                                              co-adm with
                                                data_source:
                                                https://pubmed.ncbi.nlm.nih.gov/22326470
                                                unhealthy, 18–70 years
                                                population:
                                                age:
                                                sex:
                                                food_status:
                                                n:
                                                data_source:
                                                https://pubmed.ncbi.nlm.nih.gov/22326470
                                                Abdominal pain upper 2 pts%
                                                200 mg 2 times / day multiple, oral
                                                Highest studied dose
                                                dose: 200 mg 2 times / day
                                                route: oral
                                                experiment_type: multiple
                                                dose_type: Highest studied dose
                                                co-adm with
                                                  data_source:
                                                  https://pubmed.ncbi.nlm.nih.gov/19852962
                                                  healthy, 38.0 years (range: 25-54 years)
                                                  population:
                                                  age:
                                                  sex:
                                                  food_status:
                                                  n:
                                                  data_source:
                                                  https://pubmed.ncbi.nlm.nih.gov/19852962
                                                  Diarrhea 2 pts%
                                                  200 mg 2 times / day multiple, oral
                                                  Highest studied dose
                                                  dose: 200 mg 2 times / day
                                                  route: oral
                                                  experiment_type: multiple
                                                  dose_type: Highest studied dose
                                                  co-adm with
                                                    data_source:
                                                    https://pubmed.ncbi.nlm.nih.gov/19852962
                                                    healthy, 38.0 years (range: 25-54 years)
                                                    population:
                                                    age:
                                                    sex:
                                                    food_status:
                                                    n:
                                                    data_source:
                                                    https://pubmed.ncbi.nlm.nih.gov/19852962
                                                    Photosensitivity reaction 3 pts%
                                                    200 mg 2 times / day multiple, oral
                                                    Highest studied dose
                                                    dose: 200 mg 2 times / day
                                                    route: oral
                                                    experiment_type: multiple
                                                    dose_type: Highest studied dose
                                                    co-adm with
                                                      data_source:
                                                      https://pubmed.ncbi.nlm.nih.gov/19852962
                                                      healthy, 38.0 years (range: 25-54 years)
                                                      population:
                                                      age:
                                                      sex:
                                                      food_status:
                                                      n:
                                                      data_source:
                                                      https://pubmed.ncbi.nlm.nih.gov/19852962
                                                      OverviewDrug as perpetrator​

                                                      Drug as perpetrator​

                                                      TargetModalityActivityMetaboliteClinical evidence
                                                      moderate [IC50 42.9 uM]
                                                      moderate [IC50 49.1 uM]
                                                      moderate [IC50 59.7 uM]
                                                      no
                                                      no
                                                      no
                                                      no
                                                      no
                                                      weak [IC50 131 uM]
                                                      likely (co-administration study)
                                                      Comment: Concomitant use of OLYSIO with these antiarrhythmics may result in mild increases in concentrations of these antiarrhythmics due to intestinal CYP3A4 inhibition by simeprevir
                                                      Page: 37
                                                      weak [IC50 86.1 uM]
                                                      yes [IC50 1.67 uM]
                                                      yes [IC50 25 uM]
                                                      yes (co-administration study)
                                                      Comment: Concomitant use of OLYSIO with rosuvastatin resulted in increased plasma concentrations of rosuvastatin due to inhibition of OATP1B1 by simeprevir
                                                      Page: 38
                                                      yes [IC50 3.47 uM]
                                                      yes [IC50 6.4 uM]
                                                      yes [IC50 85.9 uM]
                                                      yes (co-administration study)
                                                      Comment: Concomitant use of OLYSIO with digoxin resulted in increased concentrations of digoxin due to inhibition of P-gp by simeprevir
                                                      Page: 38
                                                      Drug as victim

                                                      Drug as victim

                                                      TargetModalityActivityMetaboliteClinical evidence
                                                      yes
                                                      yes
                                                      yes
                                                      yes
                                                      yes
                                                      yes
                                                      yes
                                                      yes
                                                      likely (co-administration study)
                                                      Comment: Concomitant use of OLYSIO with carbamazepine, oxcarbazepine, phenobarbital or phenytoin may result in significantly decreased plasma concentrations of simeprevir due to strong CYP3A induction by these anticonvulsants; Concomitant use of OLYSIO with clarithromycin or telithromycin may result in increased plasma concentrations of simeprevir due to CYP3A inhibition by these antibiotics
                                                      Page: 37
                                                      Tox targets

                                                      Tox targets

                                                      PubMed

                                                      PubMed

                                                      TitleDatePubMed
                                                      Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.
                                                      2011 Sep
                                                      Changing the face of hepatitis C management - the design and development of sofosbuvir.
                                                      2015
                                                      Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
                                                      2015 Aug 5
                                                      Hepatitis C virus: Virology, diagnosis and treatment.
                                                      2015 Jun 8
                                                      Interferon-free therapy for hepatitis C: The hurdles amid a golden era.
                                                      2015 Sep
                                                      Patents

                                                      Sample Use Guides

                                                      The recommended dose is one 150 mg capsule taken once daily with food. OLYSIO should be administered with both peginterferon alfa and ribavirin. The recommended treatment duration of OLYSIO with peginterferon alfa and ribavirin is 12 weeks, followed by either 12 or 36 additional weeks of peginterferon alfa and ribavirin depending on prior response status.
                                                      Route of Administration: Oral
                                                      The median simeprevir EC50 and EC90 values against a HCV genotype 1b replicon were 9.4 nM (7.05 ng/mL) and 19 nM (14.25 ng/mL), respectively.
                                                      Name Type Language
                                                      SIMEPREVIR
                                                      DASH   INN   USAN   VANDF   WHO-DD  
                                                      USAN   INN  
                                                      Official Name English
                                                      TMC435
                                                      Common Name English
                                                      TMC435350
                                                      Code English
                                                      TMC 435350
                                                      Code English
                                                      TMC 435
                                                      Code English
                                                      SIMEPREVIR [VANDF]
                                                      Common Name English
                                                      SIMEPREVIR [JAN]
                                                      Common Name English
                                                      SIMEPREVIR [INN]
                                                      Common Name English
                                                      SIMEPREVIR SODIUM [JAN]
                                                      Common Name English
                                                      TMC-435
                                                      Code English
                                                      SIMEPREVIR [USAN]
                                                      Common Name English
                                                      SIMEPREVIR [WHO-DD]
                                                      Common Name English
                                                      SIMEPREVIR [MI]
                                                      Common Name English
                                                      TMC-435350
                                                      Code English
                                                      Classification Tree Code System Code
                                                      NCI_THESAURUS C783
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      WHO-ATC J05AP05
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      WHO-ATC J05AE14
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      NDF-RT N0000182639
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      Code System Code Type Description
                                                      NDF-RT
                                                      N0000182638
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      PRIMARY HCV NS3/4A Protease Inhibitors [MoA]
                                                      FDA UNII
                                                      9WS5RD66HZ
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      PRIMARY
                                                      NCI_THESAURUS
                                                      C129015
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      PRIMARY
                                                      DRUG BANK
                                                      DB06290
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      PRIMARY
                                                      WIKIPEDIA
                                                      Simeprevir
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      PRIMARY
                                                      IUPHAR
                                                      7367
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      PRIMARY
                                                      NDF-RT
                                                      N0000185503
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      PRIMARY P-Glycoprotein Inhibitors [MoA]
                                                      DRUG CENTRAL
                                                      4812
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      PRIMARY
                                                      PUBCHEM
                                                      24873435
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      PRIMARY
                                                      ChEMBL
                                                      CHEMBL501849
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      PRIMARY
                                                      NDF-RT
                                                      N0000182141
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
                                                      CAS
                                                      1217263-04-1
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      NON-SPECIFIC STEREOCHEMISTRY
                                                      CAS
                                                      923604-59-5
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      PRIMARY
                                                      NDF-RT
                                                      N0000190107
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      PRIMARY Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]
                                                      INN
                                                      9432
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      PRIMARY
                                                      LACTMED
                                                      Simeprevir
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      PRIMARY
                                                      HSDB
                                                      8227
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      PRIMARY
                                                      EVMPD
                                                      SUB64783
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      PRIMARY
                                                      MERCK INDEX
                                                      M11694
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      PRIMARY
                                                      RXCUI
                                                      1482790
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      PRIMARY RxNorm
                                                      NDF-RT
                                                      N0000190108
                                                      Created by admin on Sat Jun 26 10:06:52 UTC 2021 , Edited by admin on Sat Jun 26 10:06:52 UTC 2021
                                                      PRIMARY Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]